ERBB2 and breast neoplasm: These findings support the results obtained from this study which showed lower ErbB2 mRNA expression and undetectable ErbB1 mRNA expression in Walker 256 rat breast tumour cells, thus explaining lower sensitivity of lapatinib on this cell line.